Moderna (MRNA) aims to bolster its
mRNA manufacturing capabilities in the US with a
$140 million investment. Trials for three mRNA drugs have been halted, yet the company secures a
$1.5B loan in its quest for 10% growth. The co-founder of Moderna warns of growing skepticism towards science, which may hinder mRNA technology. Despite being the most shorted stock in the S&P 500, the company announced the first delivery of
made-in-Canada mRNA vaccines.
Pfizer's mRNA flu shot outperforms standard influenza vaccines in late-stage trials, a trend replicated by
Moderna mRNA-1083. However, Moderna recently scrapped its
mRNA vaccine for congenital CMV following a Phase III failure. Moderna opens the UK's first mRNA manufacturing facility in Oxfordshire and continues to make strides in cancer therapies. The company has reported positive phase 3 data for its mRNA seasonal flu vaccine, while the RNA vaccine development funded by BARDA is being wound down. Moderna now faces renewed scrutiny following its decision to halt the development of mRNA-1647 CMV vaccine.
Moderna MRNA News Analytics from Tue, 21 Jan 2025 08:00:00 GMT to Sat, 29 Nov 2025 09:46:29 GMT -
Rating 4
- Innovation 7
- Information 8
- Rumor -3
